tbuckley/cabot-search huggingface dataset:
Analysis of clinical presentation and prognosis of diffuse large B-cell lymphoma in patients over 80 years of age
Authors: Shin Lee, Eiju Negoro, Kana Oiwa, Kei Fujita, Miyuki Ookura, Yasufumi Matsuda, Katsunori Tai, Naoko Hosono, Takanori Ueda, Takahiro Yamauchi
Journal: Annals of Oncology (2018)
P3.16-45 The Rates and Survival of Surgically-Resected Second Primary Lung Cancers in Patients Undergoing Resection of an Initial Primary Lung Cancer.
Authors: J. Varlotto, R. Voland, K. Mckie, M. Decamp, D. Maddox, P. Rava, T. Fitzgerald, K. Uy, J. Toth, P. Oliveira, M. Reed, C. Belani, J. Baima, J. Zhang, W. Walsh, M. Patel, M. Rosen, L. Mcintosh, N. Rassaei, J. Flickinger
Journal: Journal of Thoracic Oncology (2018)
The Endotoxin Delivery Protein HMGB1 Mediates Caspase-11-Dependent Lethality in Sepsis
Authors: Meihong Deng, Yiting Tang, Wenbo Li, Xiangyu Wang, Rui Zhang, Xianying Zhang, Xin Zhao, Jian Liu, Cheng Tang, Zhonghua Liu, Yongzhuo Huang, Huige Peng, Lehui Xiao, Daolin Tang, Melanie J. Scott, Qingde Wang, Jing Liu, Xianzhong Xiao, Simon Watkins, Jianhua Li, Huan Yang, Haichao Wang, Fangping Chen, Kevin J. Tracey, Timothy R. Billiar, Ben Lu
Journal: Immunity (2018)
Cystic fibrosis: triple drug regimens that target defective ion channel improve lung function, studies show
Authors: Susan Mayor
Journal: BMJ (2018)

Triple drug combinations that improve the activity of the cystic fibrosis transmembrane conductance regulator (CFTR), the anion channel that is defective or deficient in the condition, significantly improve lung function in patients with cystic fibrosis who have the most common CFTR gene mutations, two early stage randomised trials have reported.12

“These reports represent a major breakthrough in cystic fibrosis therapeutics, with the potential for improving health and possibly survival in all patients who carry the most common CFTR mutation,” said Fernando Holguin of the University of Colorado in Aurora, USA, in an accompanying editorial.3

Both trials evaluated the efficacy and safety of one of two new generation, small molecule CFTR correctors, VX-659 and VX-445. These compounds …
Statins and Multiple Noncardiovascular Outcomes
Authors: Yazhou He, Xue Li, Danijela Gasevic, Eleanor Brunt, Fiona McLachlan, Marisa Millenson, Maria Timofeeva, John P.A. Ioannidis, Harry Campbell, Evropi Theodoratou
Journal: Annals of Internal Medicine (2018)

Background: Many effects of statins on non–cardiovascular disease (non-CVD) outcomes have been reported. Purpose: To evaluate the quantity, validity, and credibility of evidence regarding associations between statins and non-CVD outcomes and the effects of statins on these outcomes. Data Sources: MEDLINE and EMBASE (English terms only, inception to 28 May 2018). Study Selection: Meta-analyses (published in English) of observational studies and of randomized controlled trials (RCTs) that examined non-CVD outcomes of statin intake. Data Extraction: Two investigators extracted data from meta-analyses and individual studies. Credibility assessments based on summary effect sizes from a random-effects model, between-study heterogeneity, 95% prediction interval, small-study effect, excess significance, and credibility ceilings were devised to classify evidence. Data Synthesis: This review explored 278 unique non-CVD outcomes from 112 meta-analyses of observational studies and 144 meta-analyses of RCTs. For observational studies, no convincing (class I) evidence, 2 highly suggestive (class II) associations (decreased cancer mortality in patients with cancer and decreased exacerbation in patients with chronic obstructive pulmonary disease), 21 suggestive (class III) associations, and 42 weak (class IV) associations were identified. One outcome from the RCTs (decreased all-cause mortality in patients with chronic kidney disease) attained a sufficient amount of evidence with no hints of bias. For adverse events, observational studies showed suggestive evidence that statins increase the risk for diabetes and myopathy. Among the RCTs, no statistically significant effects were found on myopathy, myalgia, or rhabdomyolysis. Limitations: Studies with relevant data and outcomes not included in the meta-analyses may have been missed. Credibility assessments relied on several assumptions and arbitrary thresholds. Conclusion: The absence of convincing evidence of an association between statins and non-CVD outcomes supports leaving the current recommendations unchanged. Primary Funding Source: None.
P3.12-13 Expression of the Immune Checkpoint Axis-PVR/TIGIT in Small Cell Lung Cancer
Authors: H. Yu, C. Koczara, Z. Lohinai, A. Badzio, P. Czapiewski, B. Döme, J. Moldvay, J. Fillinger, D. Gao, K. Ellison, S. Ren, C. Caldwell, C. Rivard, F. Hirsch
Journal: Journal of Thoracic Oncology (2018)
Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC)
Authors: B.A. McGregor, A.-K. Lalani, W. Xie, J.A. Steinharter, D.J. Martini, P.V. Nuzzo, N. Martinez Chanza, L.C. Harshman, M.A. Bilen, T.K. Choueiri
Journal: Annals of Oncology (2018)
Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL
Authors: Kamil Bojarczuk, Kirsty Wienand, Jeremy A. Ryan, Linfeng Chen, Mariana Villalobos-Ortiz, Elisa Mandato, Joanna Stachura, Anthony Letai, Lee N. Lawton, Bjoern Chapuy, Margaret A. Shipp
Journal: Blood (2018)
Abstract 15190: Right Heart Failure in Children After Initial Lvad Implantation Within the Pedimacs Registry Experience
Authors: Kathleen E Simpson, James K Kirklin, Ryan S Cantor, Mary Mehegan, Jacqueline M Lamour, Kristine J Guleserian, David M Peng, Elfriede Pahl
Journal: Circulation (2017)

Introduction: Use of ventricular assist device (VAD) in children has increased, but decision of left VAD (LVAD) versus biventricular VAD (BiVAD) support remains a challenge. Children who undergo in...
Risk of second primary contralateral breast cancer by molecular phenotype of the first primary breast cancer
Authors: Babette Saltzman, Kathi Malone, Janet Daling, Christopher Li
Journal: Cancer Research (2008)

554  Background:  Breast cancer survivors have a 60% higher risk of developing contralateral breast cancer compared to women who have never had breast cancer have of developing breast cancer. However, relatively little is known about what factors predispose breast cancer patients to develop contralateral breast cancer. In particular, it is largely unknown how the expression of various tumor markers and the molecular phenotypes of first primary breast cancers influence risk.  Methods:  We conducted a nested-case control study within the cohort of invasive breast cancer cases 21-64 years of age diagnosed in the Seattle-Puget Sound region from 1996-2007. Cases were women diagnosed with a first invasive breast carcinoma who subsequently developed contralateral breast cancer (n=268). Controls were frequency matched to cases by age at first breast cancer diagnosis and year of diagnosis (n=825). We abstracted available tumor marker information from pathology reports. Using conditional logistic regression we evaluated how the expression of markers in first tumors were associated with risk of developing contralateral breast cancer. In addition, we assessed risk by molecularly defined breast cancer phenotypes including luminal (ER+/PR+), basal-like (ER-/PR-/HER2-), and HER2-overexpressing (ER-/HER2+) tumors. We also conducted case-only analyses to assess the correlation between expression of markers in first and contralateral tumors.  Results:  Women with basal-like first tumors had a 3.3-fold (95% CI: 1.6-7.0) increased risk of contralateral breast cancer, and women with HER2-overexpressing first tumors had a 5.9-fold (95% CI: 0.3-101.6) increased risk, compared to women with luminal first tumors. Compared to women with HER2-negative first tumors, women with HER2-positive tumors had a 1.5-fold (95% CI: 0.9-2.5) increased risk of developing contralateral breast cancer. Women with HER2-positive first tumors were 9.2-fold (95% CI: 2.4-35.9) more likely to develop a second HER2-positive tumor compared to women whose first tumor was HER2-negative. Other tumor markers including Ki-67 and p53 did not influence contralateral breast cancer risk.  Conclusion:  These results suggest that women with particularly aggressive molecularly defined subtypes of breast cancer, including basal-like, HER2-overexpressing, and HER2+ tumors, have elevated risks of developing contralateral breast cancer. In addition to the established increased risks of mortality that these women experience, they may also have a disproportionately increased risk of contralateral breast cancer. If confirmed, these findings may also be relevant to advancing our understanding of the etiology of contralateral breast cancer.
Adapalene gel 0.1% vs. placebo as prophylaxis for anti-EGFR-induced acne-like rash: a randomized comparative evaluation
Authors: Yoshimi Fujishima, Naoko Chayahara, Motoko Tachihara, Atsushi Fukunaga, Ken Washio, Masatsugu Yamamoto, Masanori Toyoda, Kazutoshi Tobimatsu, Hisayo Doi, Naomi Mizuta, Atsushi Kawaguchi, Chikako Nishigori, Yoshihiro Nishimura, Toru Mukohara, Hironobu Minami
Journal: Annals of Oncology (2018)
Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire
Authors: Ahmad Tarhini, Yan Lin, Huang Lin, Zahra Rahman, Priyanka Vallabhaneni, Prateek Mendiratta, James F. Pingpank, Matthew P. Holtzman, Erik C. Yusko, Julie A. Rytlewski, Uma N. M. Rao, Robert L. Ferris, John M. Kirkwood
Journal: Journal for ImmunoTherapy of Cancer (2018)

<h3>Background</h3> Neoadjuvant immunotherapy utilizing novel combinations has the potential to transform the standard of care for locally/regionally advanced melanoma. We hypothesized that neoadjuvant ipilimumab in combination with high dose IFNα2b (HDI) is safe and associated with durable pathologic complete responses (pCR). <h3>Methods</h3> Patients with locally/regionally advanced melanoma were randomized to ipilimumab 3 or 10&nbsp;mg/kg × 4 doses bracketing definitive surgery, then every 12&nbsp;weeks × 4. HDI was given concurrently. We evaluated the safety and efficacy of the combination with ipilimumab 3 or 10&nbsp;mg/kg. The impact on T-cell fraction and clonality were investigated in tumor and blood. <h3>Results</h3> Thirty patients (age 37–76), 15 each at 3 and 10&nbsp;mg/kg, 18 male and 12 female were treated. Considering immune related adverse events (irAEs) of interest, more grade 3/4 irAEs were seen with ipilimumab 10&nbsp;mg/kg versus 3&nbsp;mg/kg (<i>p</i> = 0.042). Among 28 evaluable patients, 11 relapsed, of whom 5 died. Median follow-up for 17 patients who have not relapsed was 32&nbsp;months. The radiologic preoperative response rate was 36% (95% CI, 21–54); 4 patients at ipilimumab 3&nbsp;mg/kg and 6 at 10&nbsp;mg/kg and 2 (at 10&nbsp;mg/kg) later relapsed. The pCR was 32% (95% CI, 18–51); 5 patients at ipilimumab 3&nbsp;mg/kg and 4 at 10&nbsp;mg/kg and one (at 3&nbsp;mg/kg) had a late relapse. In patients with pCR, T-cell fraction was significantly higher when measured in primary melanoma tumors (<i>p</i> = 0.033). Higher tumor T-cell clonality in primary tumor and more so following neoadjuvant therapy was significantly associated with improved relapse free survival. <h3>Conclusions</h3> Neoadjuvant ipilimumab-HDI was relatively safe and exhibited promising tumor response rates with an associated measurable impact on T-cell fraction and clonality. Most pCRs were durable supporting the value of pCR as a primary endpoint in neoadjuvant immunotherapy trials. <h3>Trial registration</h3> ClinicalTrials.gov, NCT01608594. Registered 31 May 2012.
Investigator initiated clinical trial of cancer vaccine OCV-C01 in advanced and recurrent biliary tract cancer
Authors: Mutsunori Murahashi, Hisanobu Ogata, Toshihiko Okazaki, Yasuki Hijikata, Kazunari Yamada, Toshihisa Tsuruta, Junji Kishimoto, Kouta Funakoshi, Koji Todaka, Yoichi Nakanishi, Kenzaburo Tani
Journal: Annals of Oncology (2018)
Abstract 20252: Use of Ambulatory Event Monitoring in Identifying Patients With Delayed Presentation of High-Grade Atrioventricular Block Following Transcatheter Aortic Valve Replacement
Authors: Karen Ream, Amneet Sandhu, Javier Valle, Dominik Wiktor, Ryan Borne, Jehu Mathew, Alexis Tumolo, Lucas Marzec, Matthew M Zipse, Joseph Schuller, Christine Tompkins, Michael Rosenberg, Duy T Nguyen, John Carroll, John Messenger, William H Sauer, Ryan Aleong, Wendy S Tzou
Journal: Circulation (2017)

Introduction: Delayed high-grade atrioventricular block (H-AVB) following transcatheter aortic valve replacement (TAVR) has been reported, but identification of such patients post-discharge (DC) ha...
Abstract 12323: Effect of Prompt Revascularization on Outcomes in Diabetic Patients With Stable Ischemic Heart Disease Depends on Prior Myocardial Infarction Status and Mode of Revascularization
Authors: Matthew J Chung, Eric Novak, David L Brown
Journal: Circulation (2015)

Introduction: The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial found no benefit from prompt revascularization in addition to optimal medical therapy (PR+OMT) compared with OMT alone in diabetics with stable ischemic heart disease (SIHD). However, diabetics with prior myocardial infarction (PMI) are a higher risk group. Thus, we examined whether PMI status altered the effect of PR+OMT versus OMT alone on outcomes in diabetics with SIHD. Methods: BARI 2D randomized 2368 diabetics with SIHD to either PR+OMT with PCI or CABG or OMT alone. PMI was defined by reported history of MI or abnormal Q-waves on ECG. For patients with PMI and no PMI, we used Kaplan-Meier analysis to compare the rate of death, MI, stroke, congestive heart failure (CHF) and a composite of death/MI/stroke between patients randomized to PR+OMT versus OMT alone. Results: Of 2280 patients with known PMI status, 936 (41%) had PMI and 1344 (59%) did not. Baseline variables including age, sex, race, BMI, history of CHF, hypertension, hyperlipidemia, tobacco use, abnormal ejection fraction, prior revascularization, CAD severity, creatinine, glycemic control and use of guideline-directed medical therapy were similar between the two treatment strategies within each group. In patients with PMI, PR+OMT had no effect on any outcome compared with OMT alone. In those without PMI, PR+OMT was associated with higher 5-year event free rates of MI (91% vs. 85%, P = 0.002) and death/MI/stroke (81% vs. 76%, P = 0.04) compared with OMT alone, although these differences were limited to patients treated with CABG. Conclusions: In diabetics with SIHD and PMI, PR+OMT did not improve outcomes compared with OMT alone. However, in those without PMI, PR+OMT reduced the rate of MI and a composite of death/MI/stroke when treated with CABG, but not PCI. These findings, if confirmed in a prospective study, may improve outcomes in diabetics with SIHD through appropriate selection of a revascularization strategy.
A phase II study of omacetaxine mepesuccinate for patients with higher‐risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents
Authors: Nicholas J. Short, Elias Jabbour, Kiran Naqvi, Ami Patel, Jing Ning, Koji Sasaki, Graciela M. Nogueras‐Gonzalez, Prithviraj Bose, Steven M. Kornblau, Koichi Takahashi, Michael Andreeff, Gabriela Sanchez‐Petitto, Zeev Estrov, Courtney D. Dinardo, Guillermo Montalban‐Bravo, Marina Konopleva, Yesid Alvarado, Kapil N. Bhalla, Warren Fiskus, Maria Khouri, Rubiul Islam, Hagop Kantarjian, Guillermo Garcia‐Manero
Journal: American Journal of Hematology (2018)

Abstract The outcome of patients with myelodysplastic syndromes (MDSs) after failure of hypomethylating agents (HMAs) failure is poor with a median overall survival (OS) of only 4‐6 months. Omacetaxine mepesuccinate (OM) is safe and effective in myeloid malignancies but has not been studied in MDS with HMA failure. We conducted a phase II study of OM in patients with MDS or chronic myelomonocytic leukemia (CMML) who had previously failed or been intolerant to HMAs. Patients received OM at a dose of 1.25 mg/m 2 subcutaneously every 12 hours for 3 consecutive days on a 4‐ to 7‐week schedule. The primary endpoints were the overall response rate (ORR) and OS. A total of 42 patients were enrolled with a median age of 76 years. The ORR was 33%. Patients with diploid cytogenetics were more likely to respond to OM than were those with cytogenetic abnormalities (58% vs 23%, respectively; P = .03). Overall, the median OS was 7.5 months and 1‐year OS rate was 25%. Patients with diploid cytogenetics had superior OS to those with cytogenetic abnormalities (median OS 14.8 vs 6.8 months, respectively; P = .01). Two patients had ongoing response to OM of 2 years or longer (both MDS with diploid cytogenetics and RUNX1 mutation). The most common grade ≥ 3 adverse events were infections in 11 patients (26%), febrile neutropenia in 4 (10%), and hemorrhage in 3 (7%). Overall, OM was safe and active in patients with MDS or CMML who experienced HMA failure. These results support the further development of OM in this setting.
P3.CR-11 ROS1 Fusion and MET Amplification Dual Drive Coexistence in Lung Adenocarcinoma and Response to Crizotinib: A Case Report
Authors: C. Xu, W. Wang, Z. Song, Q. Zhang, W. Zhuang, Y. Chen, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2018)
Bioimaging of Intact Polycaprolactone Nanoparticles Using Aggregation‐Caused Quenching Probes: Size‐Dependent Translocation via Oral Delivery
Authors: Haisheng He, Yunchang Xie, Yongjiu Lv, Jianping Qi, Xiaochun Dong, Weili Zhao, Wei Wu, Yi Lu
Journal: Advanced Healthcare Materials (2018)

The limited information on biological fate impedes the development of more efficient polymeric nanoparticles for oral delivery of bio-macromolecules. In this study, the in vivo fate as well as the trans-epithelia transport of polycaprolactone (PCL) nanoparticles is explored by labeling with aggregation-caused quenching probes, which is capable of identifying intact nanoparticles. Live imaging and confocal laser scan microscopy confirm size-dependent absorption of PCL nanoparticles. In general, reducing particle size favors a faster and more oral absorption. Nanoparticles larger than 200 nm, such as 600 and 2000 nm, cannot be efficiently transported across the intestinal membrane. The absorbed nanoparticles (50 and 200 nm) mainly accumulate in the liver. Lymph may be the main absorption route for PCL nanoparticles, transporting 2.39 ± 1.81% and 0.98 ± 0.58% of administered 50 and 200 nm nanoparticles, respectively. Cellular uptake and transportation of PCL nanoparticles are also size dependent. Both enterocytes and M cells mediated transcytosis are involved in the transport of 50 nm PCL nanoparticles, while the M cell pathway is dominative for other nanoparticles. In conclusion, the study provides a valuable tool for bioimaging of intact polymeric nanoparticles as well as solid evidence supporting size-dependent translocation of the nanoparticles via oral delivery.
Advanced treatment line (ATL) with lenvatinib and everolimus (Len+Eve) for metastatic renal cell carcinoma (mRCC): Analysis of a national early access program (EAP)
Authors: A. Peer, M. Kolin, K. Rouvinov, D. Keizman, D. Sarid, R. Leibowitz-Amit, R. Berger, A. Sella, A. Rasco, E. Rosenbaum, C. Maurice-Dror, A. Neumann, V. Neiman
Journal: Annals of Oncology (2018)
Abstract P129: Impact of Regular Physical Activity on Prognosis After Myocardial Infarction: The OACIS Study
Authors: Masaya Usami, Yasuhiko Sakata, Daisaku Nakatani, Hiroya Mizuno, Shinichiro Suna, Sen Matsumoto, Masahiko Shimizu, Hiroshi Sato
Journal: Circulation (2016)

Introduction: It has been demonstrated that regular physical activities improve physical capacities and prognosis in survivor patients with acute myocardial infarction (AMI), especially in well-designed, relatively small patients cohorts. However, impacts of regular physical activity on prognosis are not fully elucidated in large scale, real-world settings because of varieties of confounding factors. Hypothesis: We assessed the hypothesis that regular physical activity at 3-month after AMI is an independent predictor for 5-year survival in a large cohort of post-MI patients registered in the Osaka Acute Coronary Insufficiency Study (OACIS). Methods: The OACIS is a prospective, multicenter, observational study enrolling consecutive patients with AMI at 25 collaborating hospitals in the Osaka region of Japan. Among 8957 patients registered in the OACIS, 5218 patients who reported physical activities at 3-month after MI were enrolled and were followed for 5 years. Multivariate Cox regression was used with the following variables as covariates: age, gender, BMI, HT, DM, dyslipidemia, smoking, ST-elevation MI, NYHA at 3-month after MI, reperfusion therapy, multivessel disease, depression status by SDS score, living alone, and beta-blocker, statin, antiplatelet agent, ACEI/ARB, calcium channel blocker, and diuretics therapy. Results: Regular physical activity at 3-month after MI were seen 1180 patients (22.8%, total n=5170). Cumulative mortality at 5-year after MI was 3.5%, which was lower than that in the patients without regular physical activity (3990 patients, 7.9% log-rank p&lt;0.001). However. the difference was not statistically significant in the multivariate analysis (adjusted HR 0.66, 95%CI 0.38-1.07, p=0.088). Cumulative mortality at 5-year after MI was 10.9%, which was highest (log-rank p&lt;0.001, total n=5218) in lowest quartile of maximum physical capacity (Q1: medium 4.5 Mets, n=1911) compared to 4.7% in the Q2 (median 5.5 Mets, n=681), 3.1% in the Q3 (median 6.5 Mets, n=1261), and 2.7% in the Q4 (median 7.5 Mets, n=1365). Cumulative mortality at 5-year after MI was highest (9.9%) in the patients’ activity changed from active to inactive after MI and was lowest (3.1%) in those changed from inactive to active (log-rank p&lt;0.001, total n=5204). Factors which related to start regular exercise after MI are male (OR 1.91), statin (1.59), and beta-blocker (1.33), whereas to give up was NYHA&gt;2 (OR 0.36, 95%CI 0.23-0.55, p=0.001). Frequency of cardiac death was higher in the patients without regular physical activity than with regular physical activity. Conclusion: Regular physical activity apparently related to better prognosis after AMI, but was not an independent predictor for 5-year mortality.
Pathological grade of tumorregression after neoadjuvant chemotherapy with doxorubicin/ifosfamid and regional hyperthermia correlates with survival outcomes in patients with high-risk soft tissue sarcoma
Authors: G.-E. Schuebbe, T. Knösel, H.R. Dürr, M. Angele, F. Röder, S. Abdel-Rahman, A. Alig, R.D. Issels, D. Di Gioia, L.H. Lindner
Journal: Annals of Oncology (2018)
First analysis of patients (p) with stage IV non-small cell lung cancer (NSCLC) of the thoracic tumor registry (RTT) of the Spanish Lung Cancer Group (SLCG)
Authors: E. Carcereny Costa, D. Rodriguez-Abreu, M. Guirado, R. López-Castro, B. Massutí, J. Bosch Barrera, E. Nogueron Martnez, M.A. Sala Gonzalez, M. Domine Gomez, E. Del Barco Morillo, S. Cerezo Gonzalez, M. Dorta Suarez, J. Casal Rubio, C. Camps, M.A. Muñoz, R. de las Peñas, J.A. Ortega dominguez, J.L. Gonzalez-Larriba, R. Bernabe Caro, M. Provencio Pulla
Journal: Annals of Oncology (2018)
Tranilast inhibits TGF-beta-induced EMT and invasion/metastasis via the suppression of smad4 in lung cancer cell lines
Authors: K. Takahashi, S. Nishikawa, R. Miyata, M. Noguchi, H. Ishikawa, Y. Yutaka, D. Nakajima, M. Hamaji, A. Ohsumi, T. Menju, F. Chen-Yoshikawa, T. Sato, M. Sonobe, H. Date
Journal: Annals of Oncology (2018)